NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $21.01 -0.01 (-0.05%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BBC alerts:Sign Up Key Stats Today's Range$20.93▼$21.0850-Day Range$18.22▼$22.4352-Week Range$13.42▼$31.65Volume6,586 shsAverage Volume47,599 shsMarket Capitalization$14.71 millionAssets Under Management$14.76 millionDividend Yield1.09%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF Overview The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus. Read More Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.56%0.51%0.53%Other Expenses0.00%0.47%0.56%0.59%0.56%Total Expense0.79%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.79%0.60%0.63%0.58%0.60% Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address BBC ETF News HeadlinesBBC Virtus LifeSci Biotech Clinical Trials ETFMay 23, 2025 | seekingalpha.comFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | benzinga.comCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.August 8 at 2:00 AM | Brownstone Research (Ad)Tech ETFs on the Rise After Four Weeks in Deep RedAugust 19, 2024 | theglobeandmail.comVirtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatJuly 20, 2024 | lse.co.ukSee More Headlines BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $23.94 at the beginning of 2025. Since then, BBC stock has decreased by 12.2% and is now trading at $21.0090. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and GE Aerospace (GE). Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings119 Fund Statistics Assets Under Management$14.76 million Average Daily Volume$43.81 thousand Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers, LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume6 Put Options1 Call Options6 Short Interest5,700 shs Miscellaneous Outstanding Shares700,000Beta1.08 Creation Unit50,000 Creation Fee$500.00 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 BBC HoldingsSana Biotechnology (NASDAQ:SANA)Holding Weight: 1.51%Verve Therapeutics (NASDAQ:VERV)Holding Weight: 1.38%Cogent Biosciences (NASDAQ:COGT)Holding Weight: 1.36%Intellia Therapeutics (NASDAQ:NTLA)Holding Weight: 1.27%AbCellera Biologics (NASDAQ:ABCL)Holding Weight: 1.23%Terns Pharmaceuticals (NASDAQ:TERN)Holding Weight: 1.20%Bny Mellon Cash Reserve UsdHolding Weight: 1.09%Rapport Therapeutics (NASDAQ:RAPP)Holding Weight: 1.07%Centessa Pharmaceuticals (NASDAQ:CNTA)Holding Weight: 1.06%Pharvaris (NASDAQ:PHVS)Holding Weight: 1.06%Full Holdings DetailsBBC Sector ExposureBBC Industry Exposure This page (NYSEARCA:BBC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.